The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro

详细信息    查看全文

• 作者：Claudia Alteri^a ; Matteo Surdo^a ; Velia Chiara Di Maio^a ; Fabiola Di Santo^a ; Giosuè ; Costa^b ; Lucia Parrotta^b ; Isabella Romeo^b ; Caterina Gori^c ; Maria Mercedes Santoro^a ; Valentina Fedele^c ; Stefania Carta^c ; Fabio Continenza^c ; Carmela Pinnetti^c ; Rita Bellagamba^c ; Giuseppina Liuzzi^c ; Nicoletta Orchi^c ; Alessandra Latini^d ; Ada Bertoli^a ; ^e ; Enrico Girardi^c ; Stefano Alcaro^b ; Massimo Giuliani^d ; Nicola Petrosillo^c ; Massimo Andreoni^a ; ^e ; Andrea Antinori^c ; Antonella d&rsquo ; Arminio Monforte^f ; Francesca Ceccherini-Silberstein^a ; Anna Artese^b ; Carlo Federico Perno^a ; ^c ; ^e ; ^{cf.perno@uniroma2.it} ; Valentina Svicher^a ; ^{valentina.svicher@uniroma2.it}
• 关键词：HIV-1 ; HAART ; Reverse transcriptase ; Virological success ; Docking analysis
• 刊名：Journal of Global Antimicrobial Resistance
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：7
• 期：Complete
• 页码：1-7
• 全文大小：445 K
• 卷排序：7

文摘

Role of baseline HIV-1 RT polymorphisms on response to TDF + FTC-based HAART was defined. A98S mutation increased virological success at Week 24 of treatment. In vitro and structural data support that A98S increased susceptibility to TDF and FTC. These findings may help clinicians in the selection of the optimal NRTI backbone.